Clinical Outcomes of Aflibercept in AMD and DME

What clinical outcomes support aflibercept treatment of wet AMD and diabetic macular edema?

Aflibercept treatment for wet AMD and diabetic macular edema is supported by visual acuity improvements equivalent to ranibizumab and superior to laser photocoagulation, significant anatomical improvements including central retinal thickness reductions and diabetic retinopathy severity improvements, clinically meaningful quality of life gains, and a safety profile comparable to other anti-VEGF agents with the advantage of less frequent dosing.

Abstract

Aflibercept treatment for wet age-related macular degeneration produces visual acuity outcomes equivalent to ranibizumab, with both treatments showing similar mean BCVA changes (within 0.5 letters) and approximately 32% of patients gaining ≥15 letters at one year. Anatomical outcomes were also similar, with comparable proportions achieving dry retina (RR 1.06, 95% CI 0.98 to 1.14) and equivalent choroidal neovascularization area reductions. For diabetic macular edema, aflibercept demonstrated statistically significant superiority over laser photocoagulation, with mean BCVA gains of 10.5-13.6 letters compared to -0.5 to 1.2 letters for laser (p<0.0001), and central retinal thickness reductions of 183-195 μm versus 66-73 μm for laser (p<0.0001). At 148 weeks, 35.8-42.9% of aflibercept-treated eyes gained ≥15 letters versus 13.6-18.9% with laser. Aflibercept showed non-inferiority to bevacizumab (mean improvement 15.0 versus 14.0 letters, p=0.37) and better anatomical outcomes than ranibizumab in real-world practice (central subfield thickness reduction -114.4 μm versus -87.8 μm, p<0.01). Quality of life improved meaningfully in both conditions, with NEI VFQ-25 total score gains of +6.11 points in DME and clinically significant improvements across multiple subscales in wet AMD. The safety profile was comparable to other anti-VEGF agents, with serious systemic adverse events similar to ranibizumab (RR 0.99, 95% CI 0.79 to 1.25) and no new safety signals identified in long-term use. The every-8-weeks maintenance dosing regimen after initial loading reduced treatment burden compared to monthly regimens while maintaining efficacy.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Results from Elicit search
n = 200

Papers included for extraction
n = 10

Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of Semantic Scholar and OpenAlex.

We ran this query: “What clinical outcomes support aflibercept treatment of wet AMD and diabetic macular edema?” The search returned 200 total results from Elicit.

Screening

We screened in sources based on their abstracts that met these criteria:

• Target Population: Does the study include patients diagnosed with wet AMD (neovascular age-related macular degeneration) or diabetic macular edema?
• Intervention: Does the study examine aflibercept (Eylea) administered as intravitreal injection?
• Clinical Outcomes: Does the study report clinical outcomes related to visual function, anatomical changes, or safety?
• Study Design: Is the study a randomized controlled trial, controlled clinical trial, large prospective cohort study (n≥50), or systematic review/meta-analysis?
• Follow-up Duration: Does the study have a minimum 12-week follow-up period?
• Aflibercept Analysis: Can aflibercept outcomes be separately analyzed in this study?
• Study Quality and Accessibility: Is the study NOT a case report, case series with <10 patients, editorial/commentary, or conference abstract without full-text publication?
• Study Scope: Does the study focus on ophthalmic indications and specifically on wet AMD or diabetic macular edema?

Data extraction

We extracted each data column below from each paper:

• Study Design: Extract study design and population characteristics for aflibercept studies in wet AMD or diabetic macular edema, including study type, sample size, patient population, baseline disease characteristics, comparator group(s), and follow-up duration.

• Visual Outcomes: Extract all visual acuity and functional vision outcomes, including best-corrected visual acuity (BCVA) changes, proportion gaining ≥15 letters, proportion losing ≥15 letters, and time points assessed.

• Anatomical Outcomes: Extract morphological and anatomical outcomes, including central retinal thickness changes and diabetic retinopathy severity scale improvements.

• Quality of Life: Extract patient-reported outcomes and quality of life measures, including NEI VFQ-25 scores and functional vision assessments.

• Safety Profile: Extract safety and adverse event data including serious ocular and systemic adverse events.

• Treatment Regimen: Extract aflibercept dosing and administration details, including dose administered and maintenance schedule.

• Comparative Effectiveness: Extract comparative effectiveness data when aflibercept is compared to other treatments.

• Key Limitations: Extract study limitations affecting interpretation of aflibercept outcomes.

Results

Characteristics of included studies

The systematic review included 10 sources examining aflibercept treatment for wet AMD and diabetic macular edema. These comprised randomized controlled trials and observational studies.

The studies represented diverse designs, with five focusing on wet AMD and five on DME. Most studies were randomized controlled trials, with comparators including ranibizumab, bevacizumab, and laser photocoagulation. Follow-up durations ranged from 52 weeks to 3 years.

Effects

Visual Acuity Outcomes in Wet AMD

Aflibercept demonstrated substantial and sustained visual acuity improvements in wet AMD across multiple studies.

Visual Acuity Outcomes in Diabetic Macular Edema

Aflibercept demonstrated consistent superiority over laser photocoagulation and non-inferiority to other anti-VEGF agents in DME.

Anatomical Outcomes

Aflibercept produced significant anatomical improvements in both wet AMD and DME.

Vision-Related Quality of Life

Quality of life assessments demonstrated clinically meaningful improvements with aflibercept treatment.

Safety Profile

The safety profile of aflibercept was generally favorable and comparable to other anti-VEGF agents.

Treatment Regimens

Aflibercept was administered at a dose of 2 mg across all studies. Two primary dosing regimens emerged:

• Every 4 weeks regimen (2q4): Monthly injections throughout the treatment period.
• Every 8 weeks regimen (2q8): The more common regimen involved 3-5 initial monthly loading doses followed by maintenance dosing every 8 weeks.

The eight-week dosing regimen represented reduced treatment requirements compared to monthly dosing regimens and offered the potential to reduce treatment burden and risks from frequent injections.

Comparative Effectiveness

Aflibercept demonstrated non-inferiority to ranibizumab in wet AMD and superiority to laser photocoagulation in DME, while showing comparable effectiveness to bevacizumab.

Versus Ranibizumab in Wet AMD:

In the VIEW trials, aflibercept regimens were noninferior and clinically equivalent to ranibizumab, with all aflibercept groups within 0.5 letters of ranibizumab for mean change in BCVA.

Versus Laser in DME:

Aflibercept demonstrated statistically significant superiority over laser photocoagulation in improving BCVA and reducing DME.

Versus Bevacizumab in DME:

In the direct comparison of aflibercept monotherapy versus bevacizumab-first, no significant difference in visual outcomes was found over 2 years.

Key Limitations

• Generalizability limitations and potential biases were noted across studies.

References

• Heier et al. (2012)
• Jhaveri et al. (2022)
• Chen et al. (2020)
• Ruiz-Moreno (2015)
• Heier (2016)
• Gabrielle (2022)
• Sarwar et al. (2016)
• Carrasco et al. (2021)
• Yuzawa et al. (2015)
• Garweg et al. (2019)